The Persistent Threat of Group A Streptococcus in New Zealand
Group A Streptococcus (GAS), commonly known as Strep A, is a bacterium responsible for a spectrum of illnesses ranging from mild sore throats and skin infections to severe invasive diseases and post-infectious complications like acute rheumatic fever (ARF) and rheumatic heart disease (RHD). In New Zealand, Strep A poses a significant public health challenge, particularly among Māori and Pacific children, where rates of ARF are 36 and 80 times higher, respectively, than in other ethnic groups. In 2024 alone, the country recorded 208 new rheumatic fever cases, underscoring the urgency for targeted research. University of Auckland-led initiatives are at the forefront, revealing the intricate strain dynamics driving these disparities.
New Zealand's unique epidemiology, influenced by overcrowding, socioeconomic factors, and cultural contexts, amplifies Strep A's impact. Invasive GAS infections, now notifiable since October 2024, strain healthcare resources, with Auckland alone incurring over $13.2 million in annual hospital costs for severe cases, excluding RHD expenses. This backdrop has spurred academic efforts to decode the pathogen's complexity and pave the way for effective interventions.
Launch and Vision of the Rapua Strep A Research Programme
The Rapua te mea ngaro ka tau programme, meaning 'seeking that which is hidden', was established in 2022 under the leadership of Associate Professor Nikki Moreland at the University of Auckland's Department of Molecular Medicine and Pathology. Funded with $10 million over 10 years by the Health Research Council of New Zealand, Rapua integrates community, laboratory, and clinical workstreams to accelerate Strep A vaccine development tailored to Aotearoa's needs.
Key pillars include genomic surveillance to track circulating strains, immunoassay development for vaccine efficacy testing, and community engagement with Māori and Pacific leaders like Associate Professor Anneka Anderson (Kāi Tahu, Kāti Māmoe). Collaborations extend to the University of Otago and international partners, fostering a multidisciplinary approach. The programme's website, Strep A Insights, serves as a hub for findings and whānau stories.
Unveiling Strain Diversity Through Genomic Epidemiology
A landmark 2023 Lancet study, part of Rapua's laboratory efforts, sequenced 469 GAS isolates from Auckland schoolchildren aged 5-14, uncovering 65 sequence clusters across 49 emm-types—a Simpson’s reciprocal index of 20.2, blending high-income country (HIC) and low-middle income country (LMIC) patterns. Prevalent types like emm1 (13%), emm89 (8.5%), and emm12 (7.5%) showed global introductions and local expansions, including the M1UK lineage now dominant in invasive cases.
Pattern D strains (e.g., emm53), more common in Māori and Pacific throats (22% vs. 11.4% in NZ European/Other), challenge traditional tissue tropism views and link to ARF precursors. This diversity, with over 200 known global strains, explains vaccine challenges: M-protein vaccines like StreptAnova cover 70-79%, lower in Pacific groups, while T-antigen or multi-component options exceed 99%. University of Auckland's Maurice Wilkins Centre supports this genomic prowess.
Recent immunity studies reveal 'striking' functional antibody differences across strains, advocating multi-target vaccines.
Epidemiological Insights from Auckland's High-Burden Setting
A 2025 Lancet Western Pacific study captured severe acute GAS incidence in Auckland: 1 in 2,000 hospitalized annually, spanning necrotizing fasciitis to bacteremia. Community swab analysis (1.5 million, 2018-2024) linked COVID restrictions to RF drops (2.2 to 8.0 per 100,000), affirming Strep A's role. Associate Professor Rachel Webb notes Auckland's diversity makes it ideal for vaccine trials.
Photo by Amos Haring on Unsplash
Addressing Health Inequities for Māori and Pacific Communities
Māori and Pacific peoples bear the brunt, with cultural perspectives shaping Rapua's community arm. A February 2026 PLOS Global Public Health paper highlights desires for whānau ora delivery, cultural safety, and addressing social determinants like housing. Initiatives like iSOoTH study sore throats in schools, emphasizing kaupapa Māori methods.
Explore higher education opportunities in New Zealand for roles in equity-focused health research.
Advances in Laboratory and Clinical Infrastructure
Rapua bolsters U Auckland labs for opsonophagocytic assays and sequencing, supporting the RF Platform Trial—a world-first adaptive trial for ARF/RHD treatments, expandable to vaccines. Partners include LabPLUS and global sites, building NZ's trial capacity.
Path to a Tailored Strep A Vaccine
Vaccine timelines optimistically point to 7-10 years, per Moreland. Challenges: strain variability necessitates broad coverage; Rapua data informs candidates like those from Vaxcyte or IvyX, tested locally. Multi-component strategies promise equity.
Māori/Pacific Perspectives StudyChallenges, Collaborations, and Global Implications
Funding sustains surveillance amid post-COVID surges; international ties (e.g., Doherty Institute) enhance genomics. Rapua positions NZ universities as leaders, potentially halving global RHD (46 million affected).
Future Outlook and Calls to Action
Rapua exemplifies university-driven impact. Aspiring researchers can pursue research jobs or career advice. Check Rate My Professor for insights into NZ academics. For opportunities, visit university jobs and higher ed jobs.
